Clinical trials: First Line Treatment
Breast Neoplasms
Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of sunitinib combined with docetaxel versus docetaxel, administered as first-line treatment, in patients with unresectable locally recurrent or…
- Trial name
- SUN 1064 (NCT00393939)
- Testing
- Sunitinib malate, Taxotere
- Where
- 144 sites in United States, Argentina and 25 more
- Volunteers
- 594 people
- Sponsor
- Pfizer
Quality of Life, Breast Neoplasm Female
QOL of Women With HR-Positive Metastatic BC Treated in the First-line Setting: Comparison Between Public and Private Institutions.
Assess the quality of life in patients with hormone receptor positive, human epidermal growth factor receptor-type 2 negative metastatic breast cancer treated in first line (patients with new metastasis or recurrence during…
- Trial name
- BRAVE (NCT05287139)
- Testing
- Quality of Life
- Where
- Brazil
- Volunteers
- 202 people
- Sponsor
- Beneficência Portuguesa de São Paulo
Gastroesophageal Adenocarcinoma, First Line Therapy
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
The ZANGEA trial is a open-label, single arm, multicenter phase II trial assessing the efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in patients with metastatic gastroesophageal adenocarcinoma (GEA).
- Conditions
- Gastroesophageal Adenocarcinoma, First Line Therapy, HER2 + Gastric Cancer, PDL-1
- Trial name
- ZANGEA (NCT07176312)
- Testing
- Zanidatamab, Pembrolizumab, mFOLFOX
- Where
- 20 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Esophageal Cancer
Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer
This is a multi-center, open label, randomized phase II trial for patients with previously untreated metastatic or locally advanced esophagogastric cancer, using a pick the winner design to identify the best combination therapy…
- Trial name
- LyRICX (NCT03764553)
- Testing
- Liposomal Irinotecan, Carboplatin, Capecitabine
- Where
- 34 sites in Netherlands
- Volunteers
- 320 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Ovarian Cancer
Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer
The PAOLA-1 trial demonstrated that for HRD-positive patients who received first-line chemotherapy combined with bevacizumab, sequential maintenance therapy with olaparib plus bevacizumab yielded a progression-free survival (PFS)…
- Trial name
- NCT07647653
- Testing
- Olaparib+Bevacizumab, Fluzoparib+Bevacizumab
- Volunteers
- 120 people
- Sponsor
- Shandong University
Essential Hypertension
Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: The StayOnDiur Study
Background: The use of thiazide diuretics in the treatment of hypertension (HT) is widely considered a first line treatment, given the efficacy and low cost of this class of drugs.
- Trial name
- stayondiur (NCT00408512)
- Testing
- thiazides, Non thiazidic treatment
- Where
- Italy
- Volunteers
- 2,500 people
- Sponsor
- Federico II University
Helicobacter Pylori Infection
Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy
(1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H.
- Trial name
- NCT07358130
- Testing
- vonoprazan, tripotassium dicitrate bismuthate, amoxicilline, rabeprazole, tripotassium dicitrate bismuthate, tetracycline, metronidazole
- Where
- Taiwan
- Volunteers
- 552 people
- Sponsor
- Kaohsiung Medical University
Advanced Pancreatic Ductal Adenocarcinoma
ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.
This study is testing whether adding three drugs, All-Trans Retinoic Acid (ATRA), SDK002 (also called Arsenic Trioxide or ATO), and tislelizumab, to standard chemotherapy is safe for people with advanced pancreatic cancer.
- Trial name
- ATARI-PDAC (NCT07348107)
- Testing
- ATRA, Arsenic Trioxide (ATO), Gemcitabine
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Daniel Breadner
Colorectal Cancer
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
The purposes of this study are to determine whether administering escalating doses of cetuximab in patients with no early skin toxicity could delay the progression of disease in a significant proportion of patients and to study…
- Trial name
- Everest2 (NCT01251536)
- Testing
- Dose escalation of cetuximab, Standard first line treatment with cetuximab + Folfiri
- Where
- 30 sites in Austria, Belgium and 3 more
- Volunteers
- 108 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Non-small Cell Lung Cancer
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
Clinical trial results demonstrate that anti-PD-1 antibodies prolonged OS to approximately 9 months compared with 6 months in docetaxel group.
- Trial name
- NCT03150875
- Testing
- IBI308, Docetaxel
- Where
- 2 sites in China
- Volunteers
- 290 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Colorectal Neoplasms
Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer
Preclinical study has shown that human colorectal cancer cells harboring KRAS or BRAF mutations are selectively killed by high levels of ascorbic acid (AA). High dose of AA aslo impairs tumor growth in Apc/KRASG12D mutant mice.
- Trial name
- Vitality (NCT02969681)
- Testing
- ascorbic acid, Chemotherapy
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7
This is a retrospective study that retrospectively included patients with intermediate and advanced HCC beyond up to seven who received first-line treatment with PD-1/PD-L1 inhibitors and anti-angiogenic agents combined…
- Trial name
- NCT06423144
- Testing
- TACE/HAIC, PD-1/PD-L1 inhibits and anti-angiogenic agents
- Volunteers
- 150 people
- Sponsor
- Shanghai Zhongshan Hospital
Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
A randomized controlled phase II study exploring first-line treatment options for recurrent/metastatic MSI-H gastric cancer
- Trial name
- NCT07127822
- Testing
- Iparomlimab and Tuvonralimab, First line chemotherapy plus PD-1/PD-L1 antibody
- Where
- 10 sites in China
- Volunteers
- 106 people
- Sponsor
- Peking University
Extensive Stage Small Cell Lung Cancer
Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC
The efficacy of PD-1/PD-L1 combined with chemotherapy in the treatment of extensive small-cell lung cancer is still unsatisfactory. PD-1/PD-L1 combined with chemotherapy and anti-angiogenic drugs may achieve better efficacy.
- Trial name
- NCT05001412
- Testing
- Camrelizumab; apatinib; carboplatin; etoposide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhou Chengzhi
Chronic Myelogenous Leukemia
Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
The study was a local multicentric, open-label, non-randomized phase II study of nilotinib as a first line treatment in adult patients with newly-diagnosed Philadelphia chromosome-positive (Ph+) and chronic phase myeloid leukemia…
- Trial name
- NCT01274351
- Testing
- Nilotinib
- Where
- 13 sites in Turkey (Türkiye)
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
Non Hodgkin Lymphoma
Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL
The purpose of the study is to demonstrate that oral fludarabine phosphate is comparable to i.v. formulation used in combination with mitoxantrone in terms of efficacy, safety and risk/benefit profile
- Trial name
- NCT00185445
- Testing
- Fludarabine Phosphate (Fludara)
- Where
- 14 sites in Italy
- Volunteers
- 62 people
- Sponsor
- Genzyme, a Sanofi Company
Non Small Cell Lung Cancer
A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NSCLC (NCT00583830)
- Testing
- Mapatumumab, Paclitaxel, Carboplatin
- Where
- 33 sites in United States, Germany and 2 more
- Volunteers
- 111 people
- Sponsor
- Human Genome Sciences Inc.
Stage I Multiple Myeloma, Stage II Multiple Myeloma
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
This randomized phase III trial compares bortezomib, dexamethasone, and lenalidomide with bortezomib and dexamethasone to see how well they work in treating patients with multiple myeloma previously treated with dexamethasone.
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00522392
- Testing
- bortezomib, lenalidomide, dexamethasone
- Where
- 276 sites in United States, South Africa
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia (AML)
Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC
The goal of this non-interventional study is to evaluate quality of life (QoL) in adult patients with newly diagnosed IDH1 R132-mutated AML who are not eligible to receive standard induction chemotherapy and who are treated with…
- Trial name
- CONFIDHENCE (NCT06181734)
- Testing
- Ivosidenib
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- iOMEDICO AG
Non-Small Cell Lung Cancer With HER2- Mutations
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
The study is being conducted to evaluate the efficacy, and safety of SHR-A1811 versus Standard of Care as first-line treatment of advanced or metastatic Non-Small Cell Lung Cancer with HER2- Mutations
- Trial name
- NCT06430437
- Testing
- SHR-A1811, PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.